cached image

David A. Tuveson, Ph.D., MD - Publications

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 

122 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Froeling FE, Robine N, Hubert B, Zody M, Oschwald D, Varmus HE, Sawyers CL, Tuveson DA. Abstract 5128: Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York Cancer Research. 79: 5128-5128. DOI: 10.1158/1538-7445.Am2019-5128  0.4
2016 Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget. PMID 27244881 DOI: 10.18632/Oncotarget.9551  0.92
2016 Baker LA, Tiriac H, Clevers H, Tuveson DA. Modeling pancreatic cancer with organoids. Trends in Cancer. 2: 176-190. PMID 27135056 DOI: 10.1016/J.Trecan.2016.03.004  0.92
2016 Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Sakai K, Kim YS, Engle D, Campbell F, Palmer D, Ko JH, Tuveson DA, et al. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nature Cell Biology. PMID 27088855 DOI: 10.1038/Ncb3340  0.92
2016 Espana-Agusti J, Zou X, Wong K, Fu B, Yang F, Tuveson DA, Adams DJ, Matakidou A. Generation and Characterisation of a Pax8-CreERT2 Transgenic Line and a Slc22a6-CreERT2 Knock-In Line for Inducible and Specific Genetic Manipulation of Renal Tubular Epithelial Cells. Plos One. 11: e0148055. PMID 26866916 DOI: 10.1371/Journal.Pone.0148055  0.92
2015 Jenkinson C, Elliott V, Evans A, Oldfield L, Jenkins RE, O'Brien DP, Apostolidou S, Gentry-Maharaj A, Fourkala EO, Jacobs I, Menon U, Cox TF, Campbell F, Pereira SP, Tuveson DA, et al. Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26573598 DOI: 10.1158/1078-0432.Ccr-15-0879  0.92
2015 Rosati A, Basile A, D'Auria R, d'Avenia M, De Marco M, Falco A, Festa M, Guerriero L, Iorio V, Parente R, Pascale M, Marzullo L, Franco R, Arra C, Barbieri A, ... ... Tuveson DA, et al. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nature Communications. 6: 8695. PMID 26522614 DOI: 10.1038/Ncomms9695  0.92
2015 Hwang CI, Boj SF, Clevers H, Tuveson DA. Pre-clinical Models of Pancreatic Ductal Adenocarcinoma. The Journal of Pathology. PMID 26419819 DOI: 10.1002/Path.4651  0.92
2015 Serrao EM, Kettunen MI, Rodrigues TB, Dzien P, Wright AJ, Gopinathan A, Gallagher FA, Lewis DY, Frese KK, Almeida J, Howat WJ, Tuveson DA, Brindle KM. MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model. Gut. PMID 26347531 DOI: 10.1136/Gutjnl-2015-310114  0.92
2015 Ponz-Sarvise M, Tuveson DA, Yu KH. Mouse Models of Pancreatic Ductal Adenocarcinoma. Hematology/Oncology Clinics of North America. 29: 609-617. PMID 26226900 DOI: 10.1016/J.Hoc.2015.04.010  0.92
2015 Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1. Cell. 162: 259-70. PMID 26144316 DOI: 10.1016/J.Cell.2015.06.017  0.92
2015 Espana-Agusti J, Tuveson DA, Adams DJ, Matakidou A. A minimally invasive, lentiviral based method for the rapid and sustained genetic manipulation of renal tubules. Scientific Reports. 5: 11061. PMID 26046460 DOI: 10.1038/Srep11061  0.92
2015 Neesse A, Algül H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. PMID 25994217 DOI: 10.1136/Gutjnl-2015-309304  0.92
2015 Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia AM, Höfling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem RR, ... ... Tuveson DA, et al. ADAM8 as a drug target in pancreatic cancer. Nature Communications. 6: 6175. PMID 25629724 DOI: 10.1038/Ncomms7175  0.92
2015 Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proceedings of the National Academy of Sciences of the United States of America. 112: E536-45. PMID 25624498 DOI: 10.1073/Pnas.1418163112  0.92
2015 Saiyin H, Ardito-Abraham CM, Wu Y, Wei Y, Fang Y, Han X, Li J, Zhou P, Yi Q, Maitra A, Liu JO, Tuveson DA, Lou W, Yu L. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. The Journal of Pathology. 236: 142-54. PMID 25561062 DOI: 10.1002/Path.4506  0.92
2015 Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, ... ... Tuveson DA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 160: 324-38. PMID 25557080 DOI: 10.1016/J.Cell.2014.12.021  0.92
2015 Naguib A, Bencze G, Engle DD, Chio II, Herzka T, Watrud K, Bencze S, Tuveson DA, Pappin DJ, Trotman LC. p53 mutations change phosphatidylinositol acyl chain composition. Cell Reports. 10: 8-19. PMID 25543136 DOI: 10.1016/j.celrep.2014.12.010  0.92
2014 Chio IIC, Yordanov G, Tuveson DA. MAX-ing out MYC: A novel small molecule inhibitor against MYC-dependent tumors Journal of the National Cancer Institute. 106. PMID 25430851 DOI: 10.1093/Jnci/Dju365  0.92
2014 Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, ... ... Tuveson DA, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 159: 80-93. PMID 25259922 DOI: 10.1016/J.Cell.2014.08.007  0.92
2014 Corbo V, Ponz-Sarvise M, Tuveson DA. The RAS and YAP1 dance, who is leading? The Embo Journal. 33: 2437-8. PMID 25257311 DOI: 10.15252/Embj.201490014  0.92
2014 Kultti A, Zhao C, Singha NC, Zimmerman S, Osgood RJ, Symons R, Jiang P, Li X, Thompson CB, Infante JR, Jacobetz MA, Tuveson DA, Frost GI, Shepard HM, Huang Z. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. Biomed Research International. 2014: 817613. PMID 25147816 DOI: 10.1155/2014/817613  0.92
2014 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound Journal of Experimental Medicine. 211: 1503-1523. PMID 25071162 DOI: 10.1084/Jem.20140692  0.92
2014 Chandel NS, Tuveson DA. The promise and perils of antioxidants for cancer patients. The New England Journal of Medicine. 371: 177-8. PMID 25006725 DOI: 10.1056/Nejmcibr1405701  0.92
2014 Bapiro TE, Frese KK, Courtin A, Bramhall JL, Madhu B, Cook N, Neesse A, Griffiths JR, Tuveson DA, Jodrell DI, Richards FM. Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. British Journal of Cancer. 111: 318-25. PMID 24874484 DOI: 10.1038/Bjc.2014.288  0.92
2014 Davies CC, Harvey E, McMahon RFT, Finegan KG, Connor F, Davis RJ, Tuveson DA, Tournier C. Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma Cancer Research. 74: 3344-3356. PMID 24713432 DOI: 10.1016/J.Pan.2015.05.156  0.92
2014 Baumgart S, Chen NM, Siveke JT, König A, Zhang JS, Singh SK, Wolf E, Bartkuhn M, Esposito I, Heßmann E, Reinecke J, Nikorowitsch J, Brunner M, Singh G, Fernandez-Zapico ME, ... ... Tuveson D, et al. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Cancer Discovery. 4: 688-701. PMID 24694735 DOI: 10.1158/2159-8290.Cd-13-0593  0.92
2014 Neesse A, Michl P, Tuveson DA, Ellenrieder V. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. Zeitschrift FüR Gastroenterologie. 52: 360-6. PMID 24687799 DOI: 10.1055/S-0034-1366002  0.92
2014 Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut. 63: 974-83. PMID 24067278 DOI: 10.1136/Gutjnl-2013-305559  0.92
2013 Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Oncotargets and Therapy. 7: 33-43. PMID 24379681 DOI: 10.2147/Ott.S38111  0.92
2013 Li NF, Gemenetzidis E, Marshall FJ, Davies D, Yu Y, Frese K, Froeling FE, Woolf AK, Feakins RM, Naito Y, Iacobuzio-Donahue C, Tuveson DA, Hart IR, Kocher HM. RhoC interacts with integrin α5β1 and enhances its trafficking in migrating pancreatic carcinoma cells. Plos One. 8: e81575. PMID 24312560 DOI: 10.1371/Journal.Pone.0081575  0.92
2013 Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: 20212-7. PMID 24277834 DOI: 10.1073/Pnas.1320318110  0.92
2013 Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. Plos One. 8: e67330. PMID 23840665 DOI: 10.1371/Journal.Pone.0067330  0.92
2013 Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: 12325-30. PMID 23836645 DOI: 10.1073/Pnas.1300415110  0.92
2013 Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, Zhao Q, Caballero OL, Larder R, Coll AP, O'Rahilly S, ... ... Tuveson DA, et al. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. The Journal of Experimental Medicine. 210: 1137-51. PMID 23712428 DOI: 10.1084/Jem.20122344  0.92
2013 Chin L, De Sauvage F, Egeblad M, Olive KP, Tuveson D, Weiss W. Recapitulating human cancer in a mouse Nature Biotechnology. 31: 392-395. PMID 23657389 DOI: 10.1038/Nbt.2575  0.92
2013 Neesse A, Hahnenkamp A, Griesmann H, Buchholz M, Hahn SA, Maghnouj A, Fendrich V, Ring J, Sipos B, Tuveson DA, Bremer C, Gress TM, Michl P. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut. 62: 1034-43. PMID 22677720 DOI: 10.1136/Gutjnl-2012-302577  0.92
2013 Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, ... ... Tuveson DA, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 62: 112-20. PMID 22466618 DOI: 10.1136/Gutjnl-2012-302529  0.92
2012 Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4266-76. PMID 22896693 DOI: 10.1158/1078-0432.Ccr-11-3114  0.92
2012 Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, ... ... Tuveson DA, et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature. 486: 266-70. PMID 22699621 DOI: 10.1038/Nature11114  0.92
2012 Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discovery. 2: 260-9. PMID 22585996 DOI: 10.1158/2159-8290.Cd-11-0242  0.92
2012 Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to clinical trials. Drug Discovery Today. 17: 253-60. PMID 22493784 DOI: 10.1016/J.Drudis.2012.02.003  0.92
2012 Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Praseedom RK, Huguet EL, Jah A, ... ... Tuveson DA, et al. Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Pancreatology : Official Journal of the International Association of Pancreatology (Iap) ... [Et Al.]. 12: 8-15. PMID 22487467 DOI: 10.1016/J.Pan.2011.12.009  0.92
2012 Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology. 142: 1079-92. PMID 22406637 DOI: 10.1053/J.Gastro.2012.03.002  0.92
2012 Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T, Howat WJ, Jodrell DI, Tuveson DA. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. The Journal of Experimental Medicine. 209: 437-44. PMID 22351932 DOI: 10.1084/Jem.20111923  0.92
2012 Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 148: 21-3. PMID 22265397 DOI: 10.1016/J.Cell.2011.12.021  0.92
2012 Gopinathan A, Denicola GM, Frese KK, Cook N, Karreth FA, Mayerle J, Lerch MM, Reinheckel T, Tuveson DA. Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut. 61: 877-84. PMID 22157328 DOI: 10.1136/Gutjnl-2011-300850  0.92
2012 Caldwell ME, DeNicola GM, Martins CP, Jacobetz MA, Maitra A, Hruban RH, Tuveson DA. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene. 31: 1599-608. PMID 21860420 DOI: 10.1038/Onc.2011.350  0.92
2012 Mackin P, Young L, Connor F, Tuveson D. Cage to bedside: Ultrasound imaging in a mouse model of pancreatic ductal adenocarcinoma (PDA) Animal Technology and Welfare. 11: 131-134.  0.92
2011 Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA, Balkwill FR, Tuveson DA, Hagemann T. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. The Journal of Clinical Investigation. 121: 4685-99. PMID 22056382 DOI: 10.1172/Jci45797  0.92
2011 Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discovery. 1: 128-36. PMID 22043453 DOI: 10.1158/2159-8290.Cd-10-0044  0.92
2011 Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, Tuveson DA, et al. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 147: 382-95. PMID 22000016 DOI: 10.1016/J.Cell.2011.09.032  0.92
2011 Pearson HB, Perez-Mancera PA, Dow LE, Ryan A, Tennstedt P, Bogani D, Elsum I, Greenfield A, Tuveson DA, Simon R, Humbert PO. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. The Journal of Clinical Investigation. 121: 4257-67. PMID 21965329 DOI: 10.1172/Jci58509  0.92
2011 DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, ... ... Tuveson DA, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475: 106-9. PMID 21734707 DOI: 10.1038/Nature10189  0.92
2011 Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology. 141: 1486-97, 1497.e1-14. PMID 21704588 DOI: 10.1053/J.Gastro.2011.06.047  0.92
2011 Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI. A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. Cancer Chemotherapy and Pharmacology. 68: 1243-53. PMID 21431415 DOI: 10.1007/S00280-011-1613-0  0.92
2011 Tuveson D, Hanahan D. Translational medicine: Cancer lessons from mice to humans. Nature. 471: 316-7. PMID 21412332 DOI: 10.1038/471316A  0.92
2011 Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, ... ... Tuveson DA, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 469: 539-42. PMID 21248752 DOI: 10.1038/Nature09639  0.92
2011 Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut. 60: 861-8. PMID 20966025 DOI: 10.1136/Gut.2010.226092  0.92
2011 Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, ... ... Tuveson DA, et al. Exome sequencing identifies frequent mutation of the SWI/SNF Complex Gene PBRM1 in renal carcinoma Journal of Urology. 186: 1150. DOI: 10.1016/J.Juro.2011.05.019  0.92
2010 Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell. 18: 499-509. PMID 21056012 DOI: 10.1016/J.Ccr.2010.10.015  0.92
2010 Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (New York, N.Y.). 330: 827-30. PMID 21051638 DOI: 10.1126/Science.1195300  0.92
2010 Grippo PJ, Tuveson DA. Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prevention Research (Philadelphia, Pa.). 3: 1382-7. PMID 21045161 DOI: 10.1158/1940-6207.Capr-10-0258  0.92
2009 Karreth FA, DeNicola GM, Winter SP, Tuveson DA. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Molecular Cell. 36: 477-86. PMID 19917255 DOI: 10.1016/J.Molcel.2009.10.017  0.92
2009 DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. European Journal of Cancer (Oxford, England : 1990). 45: 211-6. PMID 19775620 DOI: 10.1016/S0959-8049(09)70036-X  0.92
2009 Caldwell ME, Tuveson DA. Finding and killing the CRABs of pancreatic cancer. Gastroenterology. 137: 782-5. PMID 19643193 DOI: 10.1053/J.Gastro.2009.07.035  0.92
2009 Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, ... ... Tuveson DA, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (New York, N.Y.). 324: 1457-61. PMID 19460966 DOI: 10.1126/Science.1171362  0.92
2009 Karreth FA, Tuveson DA. Modelling oncogenic Ras/Raf signalling in the mouse. Current Opinion in Genetics & Development. 19: 4-11. PMID 19201597 DOI: 10.1016/J.Gde.2008.12.006  0.92
2009 Wang L, Qi X, Shen R, Sun Y, Tuveson DA. An shRNA silencing a non-toxic transgene reduces nutrient consumption and increases production of adenoviral vectors in a novel packaging cell. Journal of Cellular Physiology. 219: 365-71. PMID 19117009 DOI: 10.1002/Jcp.21679  0.92
2008 Gopinathan A, Tuveson DA. The use of GEM models for experimental cancer therapeutics. Disease Models & Mechanisms. 1: 83-6. PMID 19048065 DOI: 10.1242/Dmm.000570  0.92
2008 Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4836-42. PMID 18676756 DOI: 10.1158/1078-0432.Ccr-07-4123  0.92
2008 Cook N, Olive KP, Frese K, Tuveson DA. K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. Methods in Enzymology. 439: 73-85. PMID 18374157 DOI: 10.1016/S0076-6879(07)00406-5  0.92
2008 Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, Stone JR, Tuveson DA, Jaenisch R, Jacks T. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis (Genes and Development (2007) 21, (694-707)) Genes and Development. 22: 277.  0.92
2007 Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Research. 67: 9518-27. PMID 17909062 DOI: 10.1158/0008-5472.Can-07-0175  0.92
2007 Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, Eckman MS, Tuveson DA, Capobianco AJ, Tybulewicz VL, Jacks T. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Research. 67: 8089-94. PMID 17804720 DOI: 10.1158/0008-5472.Can-07-2300  0.92
2007 Frese KK, Tuveson DA. Maximizing mouse cancer models. Nature Reviews. Cancer. 7: 645-58. PMID 17687385 DOI: 10.1038/Nrc2192  0.92
2007 Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Research. 67: 6075-82. PMID 17616662 DOI: 10.1158/0008-5472.Can-06-4128  0.92
2007 Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, Stone JR, Tuveson DA, Jaenisch R, Jacks T. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes & Development. 21: 694-707. PMID 17369402 DOI: 10.1101/Gad.1526207  0.92
2007 Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA, Hingorani SR. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 11: 229-43. PMID 17349581 DOI: 10.1016/J.Ccr.2007.01.017  0.92
2007 Zhang J, Liu Y, Beard C, Tuveson DA, Jaenisch R, Jacks TE, Lodish HF. Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood. 109: 5238-41. PMID 17317860 DOI: 10.1182/Blood-2006-09-047050  0.92
2007 Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 445: 661-5. PMID 17251932 DOI: 10.1038/Nature05541  0.92
2006 King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, ... ... Tuveson DA, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Research. 66: 11100-5. PMID 17145850 DOI: 10.1158/0008-5472.Can-06-2554  0.92
2006 Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5277-87. PMID 17000660 DOI: 10.1158/1078-0432.Ccr-06-0436  0.92
2006 Pérez-Mancera PA, Tuveson DA. Physiological analysis of oncogenic K-ras. Methods in Enzymology. 407: 676-90. PMID 16757361 DOI: 10.1016/S0076-6879(05)07053-9  0.92
2006 Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 108: 2041-4. PMID 16720837 DOI: 10.1182/Blood-2006-01-013490  0.92
2006 Tuveson DA, Zhu L, Gopinathan A, Willis NA, Kachatrian L, Grochow R, Pin CL, Mitin NY, Taparowsky EJ, Gimotty PA, Hruban RH, Jacks T, Konieczny SF. Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Research. 66: 242-7. PMID 16397237 DOI: 10.1158/0008-5472.Can-05-2305  0.92
2006 Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, Kloppel G, Lauwers GY, Longnecker DS, Luttges J, Maitra A, ... ... Tuveson DA, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Research. 66: 95-106. PMID 16397221 DOI: 10.1158/0008-5472.Can-05-2168  0.92
2006 Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, Tuveson DA. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Research. 66: 14-7. PMID 16397208 DOI: 10.1158/0008-5472.Can-05-3914  0.92
2005 Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harbor Symposia On Quantitative Biology. 70: 65-72. PMID 16869739 DOI: 10.1101/Sqb.2005.70.040  0.92
2005 Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Research. 65: 10280-8. PMID 16288016 DOI: 10.1158/0008-5472.Can-05-2193  0.92
2005 Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 8: 311-21. PMID 16226706 DOI: 10.1016/J.Ccr.2005.09.008  0.92
2005 Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Research. 65: 8166-73. PMID 16166291 DOI: 10.1158/0008-5472.Can-05-1650  0.92
2005 Denicola G, Tuveson DA. VAV1: a new target in pancreatic cancer? Cancer Biology & Therapy. 4: 509-11. PMID 15970675 DOI: 10.4161/Cbt.4.5.1781  0.92
2005 Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 7: 469-83. PMID 15894267 DOI: 10.1016/J.Ccr.2005.04.023  0.92
2005 Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Research. 65: 2412-21. PMID 15781657 DOI: 10.1158/0008-5472.Can-04-2423  0.92
2004 Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biology & Therapy. 3: 1058-9. PMID 15640618 DOI: 10.4161/Cbt.3.11.1302  0.92
2004 Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 119: 847-60. PMID 15607980 DOI: 10.1016/J.Cell.2004.11.004  0.92
2004 Wang LF, Hingorani SR, Tuveson DA. Detecting and diagnosing ampullary neoplasms. Cancer Biology & Therapy. 3: 657-9. PMID 15326385 DOI: 10.4161/Cbt.3.7.1051  0.92
2004 Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 5: 375-87. PMID 15093544 DOI: 10.1016/S1535-6108(04)00085-6  0.92
2004 Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. The Journal of Clinical Investigation. 113: 528-38. PMID 14966562 DOI: 10.1172/Jci20476  0.92
2004 Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America. 101: 597-602. PMID 14699048 DOI: 10.1073/Pnas.0307203101  0.92
2004 Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, ... ... Tuveson DA, et al. Erratum: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse (Cancer Cell (4) (437-450)) Cancer Cell. 5. DOI: 10.1016/S1535-6108(03)00335-0  0.92
2003 Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, ... ... Tuveson DA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4: 437-50. PMID 14706336 DOI: 10.1016/S1535-6108(03)00309-X  0.92
2003 Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes & Development. 17: 3112-26. PMID 14681207 DOI: 10.1101/Gad.1158703  0.92
2003 Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Research. 63: 5198-202. PMID 14500344  0.92
2003 Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 4: 95-8. PMID 12957284 DOI: 10.1016/S1535-6108(03)00189-2  0.92
2003 Hingorani SR, Tuveson DA. Targeting oncogene dependence and resistance. Cancer Cell. 3: 414-7. PMID 12781357 DOI: 10.1016/S1535-6108(03)00115-6  0.92
2003 Hingorani SR, Tuveson DA. In search of an early warning system for pancreatic cancer. Cancer Biology & Therapy. 2: 84-6. PMID 12673125 DOI: 10.4161/Cbt.246  0.92
2003 Hingorani SR, Tuveson DA. Ras redux: rethinking how and where Ras acts. Current Opinion in Genetics & Development. 13: 6-13. PMID 12573429 DOI: 10.1016/S0959-437X(02)00017-5  0.92
2002 Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. 347: 472-80. PMID 12181401 DOI: 10.1056/Nejmoa020461  0.92
2002 Tuveson DA, Jacks T. Technologically advanced cancer modeling in mice. Current Opinion in Genetics & Development. 12: 105-10. PMID 11790563 DOI: 10.1016/S0959-437X(01)00272-6  0.92
2001 Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes & Development. 15: 3243-8. PMID 11751630 DOI: 10.1101/Gad.943001  0.92
2001 Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Research. 61: 8118-21. PMID 11719439  0.92
2001 Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 20: 5054-8. PMID 11526490 DOI: 10.1038/Sj.Onc.1204704  0.92
2001 Tuveson DA, Fletcher JA. Signal transduction pathways in sarcoma as targets for therapeutic intervention. Current Opinion in Oncology. 13: 249-55. PMID 11429482 DOI: 10.1097/00001622-200107000-00007  0.92
2001 Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410: 1111-6. PMID 11323676 DOI: 10.1038/35074129  0.92
1999 Tuveson DA, Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene. 18: 5318-24. PMID 10498884 DOI: 10.1038/Sj.Onc.1203107  0.92
1993 Dal Porto J, Johansen TE, Čatipović B, Parfiit DJ, Tuveson D, Gether U, Kozlowski S, Fearon DT, Schneck JP. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations Proceedings of the National Academy of Sciences of the United States of America. 90: 6671-6675. PMID 8341685 DOI: 10.1073/Pnas.90.14.6671  0.92
1993 Tuveson DA, Carter RH, Soltoff SP, Fearon DT. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science (New York, N.Y.). 260: 986-9. PMID 7684160 DOI: 10.1126/Science.7684160  0.92
1991 Carter RH, Tuveson DA, Park DJ, Rhee SG, Fearon DT. The CD19 complex of B lymphocytes: Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex Journal of Immunology. 147: 3663-3671. PMID 1719083  0.92
1991 Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT. Molecular interactions of complement receptors on B lymphocytes: A CR1/CR2 complex distinct from the CR2/CD19 complex Journal of Experimental Medicine. 173: 1083-1089. PMID 1708808 DOI: 10.1084/Jem.173.5.1083  0.92
1991 Matsumoto AK, Kopicky-Burd J, Carter RH, Tuveson DA, Tedder TF, Fearon DT. Intersection of the complement and immune systems: A signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19 Journal of Experimental Medicine. 173: 55-64. PMID 1702139 DOI: 10.1084/Jem.173.1.55  0.92
Show low-probability matches.